CN1424870A - 用挑选的供体细胞实施核移植 - Google Patents
用挑选的供体细胞实施核移植 Download PDFInfo
- Publication number
- CN1424870A CN1424870A CN00813845A CN00813845A CN1424870A CN 1424870 A CN1424870 A CN 1424870A CN 00813845 A CN00813845 A CN 00813845A CN 00813845 A CN00813845 A CN 00813845A CN 1424870 A CN1424870 A CN 1424870A
- Authority
- CN
- China
- Prior art keywords
- cell
- embryo
- donorcells
- animal
- cloning
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012546 transfer Methods 0.000 title abstract description 17
- 210000004027 cell Anatomy 0.000 claims abstract description 297
- 238000000034 method Methods 0.000 claims abstract description 148
- 230000022131 cell cycle Effects 0.000 claims abstract description 67
- 241001465754 Metazoa Species 0.000 claims abstract description 52
- 230000009261 transgenic effect Effects 0.000 claims abstract description 22
- 210000002257 embryonic structure Anatomy 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 210000002308 embryonic cell Anatomy 0.000 claims abstract description 8
- 210000001161 mammalian embryo Anatomy 0.000 claims description 125
- 210000004940 nucleus Anatomy 0.000 claims description 51
- 238000010367 cloning Methods 0.000 claims description 49
- 238000002054 transplantation Methods 0.000 claims description 37
- 210000000130 stem cell Anatomy 0.000 claims description 29
- 210000002459 blastocyst Anatomy 0.000 claims description 27
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 25
- 210000001519 tissue Anatomy 0.000 claims description 20
- 238000010449 nuclear transplantation Methods 0.000 claims description 15
- 210000002950 fibroblast Anatomy 0.000 claims description 13
- 241001494479 Pecora Species 0.000 claims description 12
- 210000003855 cell nucleus Anatomy 0.000 claims description 12
- 210000003754 fetus Anatomy 0.000 claims description 12
- 210000004748 cultured cell Anatomy 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 230000001605 fetal effect Effects 0.000 claims description 11
- 238000012239 gene modification Methods 0.000 claims description 11
- 230000005017 genetic modification Effects 0.000 claims description 11
- 235000013617 genetically modified food Nutrition 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 230000004069 differentiation Effects 0.000 claims description 10
- 210000000287 oocyte Anatomy 0.000 claims description 10
- 210000000056 organ Anatomy 0.000 claims description 10
- 238000000926 separation method Methods 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 235000013336 milk Nutrition 0.000 claims description 9
- 239000008267 milk Substances 0.000 claims description 9
- 210000004080 milk Anatomy 0.000 claims description 9
- 230000007159 enucleation Effects 0.000 claims description 8
- 230000002068 genetic effect Effects 0.000 claims description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 7
- 241000009328 Perro Species 0.000 claims description 7
- 241000282994 Cervidae Species 0.000 claims description 6
- 241000283073 Equus caballus Species 0.000 claims description 6
- 241000282326 Felis catus Species 0.000 claims description 6
- 241000283984 Rodentia Species 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000000284 resting effect Effects 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 241000282898 Sus scrofa Species 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 238000001415 gene therapy Methods 0.000 claims description 4
- 210000002569 neuron Anatomy 0.000 claims description 4
- 241000251468 Actinopterygii Species 0.000 claims description 3
- 206010002027 Amyotrophy Diseases 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 3
- 230000014509 gene expression Effects 0.000 claims description 3
- 235000013372 meat Nutrition 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 210000001082 somatic cell Anatomy 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- 208000028782 Hereditary disease Diseases 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 208000024556 Mendelian disease Diseases 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 238000007877 drug screening Methods 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000005229 liver cell Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims 1
- 238000012271 agricultural production Methods 0.000 claims 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 235000013622 meat product Nutrition 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 230000000644 propagated effect Effects 0.000 claims 1
- 231100000820 toxicity test Toxicity 0.000 claims 1
- 238000009602 toxicology test Methods 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 abstract 1
- 235000021436 nutraceutical agent Nutrition 0.000 abstract 1
- 230000010190 G1 phase Effects 0.000 description 57
- 210000000805 cytoplasm Anatomy 0.000 description 35
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 29
- 229940098773 bovine serum albumin Drugs 0.000 description 29
- 230000004927 fusion Effects 0.000 description 24
- 239000002609 medium Substances 0.000 description 23
- 239000001963 growth medium Substances 0.000 description 21
- 241000283690 Bos taurus Species 0.000 description 19
- 230000035519 G0 Phase Effects 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 19
- 230000004083 survival effect Effects 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 15
- 230000011278 mitosis Effects 0.000 description 14
- 244000309466 calf Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 description 12
- 230000018199 S phase Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- 230000013020 embryo development Effects 0.000 description 10
- 230000035800 maturation Effects 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 210000004186 follicle cell Anatomy 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000000394 mitotic effect Effects 0.000 description 8
- 230000018486 cell cycle phase Effects 0.000 description 7
- 230000035606 childbirth Effects 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 235000003642 hunger Nutrition 0.000 description 7
- 230000037351 starvation Effects 0.000 description 7
- 230000001360 synchronised effect Effects 0.000 description 7
- 108010076119 Caseins Proteins 0.000 description 6
- 108010077544 Chromatin Proteins 0.000 description 6
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 6
- 210000001109 blastomere Anatomy 0.000 description 6
- 210000003483 chromatin Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000003104 tissue culture media Substances 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 102000011632 Caseins Human genes 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 239000006059 cover glass Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 4
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 230000010337 G2 phase Effects 0.000 description 3
- 206010027336 Menstruation delayed Diseases 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 210000000003 hoof Anatomy 0.000 description 3
- 238000010376 human cloning Methods 0.000 description 3
- 210000002380 oogonia Anatomy 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 2
- 241001550206 Colla Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 2
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000001840 diploid cell Anatomy 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 210000002394 ovarian follicle Anatomy 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- WGIAYBNWTYECJD-UHFFFAOYSA-N 1-ethoxypiperazine Chemical compound CCON1CCNCC1 WGIAYBNWTYECJD-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 241001124076 Aphididae Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102000011961 Maturation-Promoting Factor Human genes 0.000 description 1
- 108010075942 Maturation-Promoting Factor Proteins 0.000 description 1
- 108700011325 Modifier Genes Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003483 aging Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 238000000819 phase cycle Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000005424 photoluminescence Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000004508 polar body Anatomy 0.000 description 1
- 230000007542 postnatal development Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000016853 telophase Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000004367 thymic lymphocyte Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ337792A NZ337792A (en) | 1999-09-14 | 1999-09-14 | Nuclear transfer and use in cloning |
NZ337792 | 1999-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1424870A true CN1424870A (zh) | 2003-06-18 |
Family
ID=19927507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN00813845A Pending CN1424870A (zh) | 1999-09-14 | 2000-09-14 | 用挑选的供体细胞实施核移植 |
Country Status (8)
Country | Link |
---|---|
JP (1) | JP2004500038A (fr) |
CN (1) | CN1424870A (fr) |
AR (1) | AR032284A1 (fr) |
AU (1) | AU784371B2 (fr) |
DE (1) | DE10084987T1 (fr) |
GB (1) | GB2369828B (fr) |
NZ (1) | NZ337792A (fr) |
WO (1) | WO2001019182A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1248640T3 (da) | 2000-01-20 | 2007-02-12 | Diabcell Pty Ltd | Xenotransplantation af svineöer og deres fremstilling |
CA2509465A1 (fr) * | 2002-12-10 | 2004-06-24 | Gtc Biotherapeutics, Inc. | Procede et systeme d'utilisation d'embryons de transfert nucleaire cellulaire de cellule somatique en tant que donneurs de cellules pour un transfert nucleaire supplementaire |
JP2006081542A (ja) * | 2004-08-18 | 2006-03-30 | Institute Of Physical & Chemical Research | クローン哺乳動物の作成方法 |
JP2010075099A (ja) * | 2008-09-26 | 2010-04-08 | Japan Science & Technology Agency | 哺乳動物核移植胚のスクリーニング方法、非ヒト哺乳動物核移植胚、クローン非ヒト哺乳動物、及びスクリーニングキット |
WO2016036754A1 (fr) * | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Procédés et compositions pour assurer la modification de l'adn cible arn dépendante |
CN105483216B (zh) * | 2015-11-30 | 2019-01-15 | 四川农业大学 | 一种家兔cetp基因检测肉质育种的方法 |
CN108624621B (zh) * | 2018-01-17 | 2019-04-12 | 中国科学院上海生命科学研究院 | 非人灵长类的体细胞克隆动物的制备方法 |
MX2022011245A (es) | 2020-03-11 | 2023-01-11 | Bit Bio Ltd | Método de generación de células hepáticas. |
CN111793671A (zh) * | 2020-07-22 | 2020-10-20 | 中国农业大学 | 一种优化的适用于绵羊染色体二元流式分选的染色体悬液制备方法 |
CN112715479A (zh) * | 2021-01-06 | 2021-04-30 | 吉沙阿牛 | 一种山羊生态循环养殖方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999046982A1 (fr) * | 1998-03-16 | 1999-09-23 | Relag Pty Ltd | Transfert de noyau de cellules porcines |
-
1999
- 1999-09-14 NZ NZ337792A patent/NZ337792A/en not_active IP Right Cessation
-
2000
- 2000-09-14 AU AU74624/00A patent/AU784371B2/en not_active Ceased
- 2000-09-14 CN CN00813845A patent/CN1424870A/zh active Pending
- 2000-09-14 JP JP2001522836A patent/JP2004500038A/ja active Pending
- 2000-09-14 AR ARP000104816A patent/AR032284A1/es unknown
- 2000-09-14 GB GB0205915A patent/GB2369828B/en not_active Expired - Fee Related
- 2000-09-14 WO PCT/NZ2000/000179 patent/WO2001019182A1/fr active Application Filing
- 2000-09-14 DE DE10084987T patent/DE10084987T1/de not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU7462400A (en) | 2001-04-17 |
GB0205915D0 (en) | 2002-04-24 |
GB2369828B (en) | 2004-12-01 |
DE10084987T1 (de) | 2003-04-17 |
JP2004500038A (ja) | 2004-01-08 |
AU784371B2 (en) | 2006-03-23 |
AR032284A1 (es) | 2003-11-05 |
NZ337792A (en) | 2002-03-28 |
WO2001019182A1 (fr) | 2001-03-22 |
GB2369828A (en) | 2002-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1210066C (zh) | 用来自分化细胞的供体核克隆猪的方法 | |
CN1248288B (zh) | 用分化胎儿和成年供体细胞进行的核转移 | |
CN100335625C (zh) | 来自有蹄动物胚胎的培养内细胞团细胞系 | |
CN1200107C (zh) | 以成年体细胞胞核重建的去核卵母细胞足月发育成动物 | |
CN1230989A (zh) | 通过种间核移植制备胚胎细胞或干细胞样细胞系 | |
CN1265599A (zh) | 使用来自无血清饥饿的分化细胞的供体细胞核进行克隆 | |
CN1391605A (zh) | 多能细胞和细胞系的单雌生殖或单雄生殖产生,及其产生分化细胞和组织的用途 | |
CN1212009A (zh) | 有蹄动物胚胎干样细胞、制法及用该细胞产生转基因的有蹄动物的方法 | |
CN107937445A (zh) | 利用体细胞克隆技术制备基因敲除犬的方法 | |
CN1424870A (zh) | 用挑选的供体细胞实施核移植 | |
CN1377424A (zh) | 由衰老体细胞克隆的动物中的端粒恢复和细胞寿命延长 | |
Park et al. | Assisted reproductive techniques and genetic manipulation in the common marmoset | |
CN1280412C (zh) | 产生克隆胚胎和其子代的方法以及由所述方法生产的细胞 | |
CN1582332A (zh) | 转染gfp的克隆猪、敲除gt的克隆猪及其生产方法 | |
CN1425064A (zh) | 通过交叉物种核移植制备的胚胎或干样细胞 | |
EP1779724A1 (fr) | Construction de chimere a l'aide de cellules es | |
CN1299408A (zh) | 通过异种间的核移植产生的胚细胞或干细胞样细胞系 | |
CN1293188C (zh) | 一种将长期培养的可包括人工诱导基因改变的雌或雄体细胞的细胞核转移到去核受体细胞中实现靶向基因改变的克隆动物的方法 | |
CN1298841C (zh) | 重建胚胎中核转移后融合和活化的方法和系统 | |
CN1399513A (zh) | 用于核移植的供体细胞的制备和选择 | |
CN1377225A (zh) | 使用来自分化细胞的供体细胞或细胞核克隆猪以及多能猪的生成 | |
CN1447854A (zh) | 来自猿猴的胚胎干细胞 | |
CN1284851C (zh) | 体细胞起源的胚胎干细胞及其分化细胞 | |
KR20070101266A (ko) | 동물 체세포 핵 이식과 연관된 유사분열 방추 결함의 교정및 착상 전 배아 발달율의 최적화 방법 | |
KR20060057528A (ko) | 동물에서 체세포 핵 전이와 연관된 유사분열 방추 결함을교정하는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |